Skip to main content

UCB Medicines: Clinical Studies and Scientific Research Publication

Publications

Filter
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

Select product(s):
Select topic(s):
Phase:

*Includes seizure clusters and acute or prolonged seizures

137 result(s)

phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab versus adalimumab in plaque psoriasis.

Warren B. Richard, Blauvelt Andrew, Bagel Jerry et al.  July 08, 2021
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab versus secukinumab in plaque psoriasis.

Reich Kristian, Warren B. Richard, Lebwohl Mark et al.  July 08, 2021
phase 3

BRIVIACT® (brivaracetam) CV

Focal Onset Seizures
View

Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: post hoc pooled analysis

Brian D Moseley, Svetlana Dimova, Sami Elmoufti et al.  June 24, 2021
phase 4

CIMZIA® (certolizumab pegol)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study. 

van der Horst-Bruinsma I, van Bentum R, Verbraak F et al.  March 29, 2021
phase 2

RYSTIGGO® (rozanolixizumab-noli)

Generalized Myasthenia Gravis
View

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

Bril Vera, Benatar Michael, Andersen Henning et al.  February 09, 2021
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.

Reich Kristian, Krueger James, Blauvelt Andrew et al.  February 06, 2021
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised trial.

Gordon B. Kenneth, Foley Peter, Krueger G. James et al.  February 06, 2021
phase 3

NAYZILAM® (midazolam) CIV

Seizure Emergencies
View

Clinical pharmacokinetic and pharmacodynamic profile of midazolam nasal spray

M René Bouw, Steve S Chung, Barry Gidal et al.  February 03, 2021
phase 3

FINTEPLA® (fenfluramine)

Dravet Syndrome
View

Fenfluramine hydrochloride provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study

Joseph Sullivan, Ingrid E Scheffer, Lieven Lagae et al.  October 19, 2020
phase 2

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F 

Ralph Adams, A. Maroof, Terry Baker et al.  August 21, 2020